ClinicalTrials.gg
Active, not recruitingNCT04988295MARIPOSA-2Updated Nov 4, 2026Results posted

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

A Phase 3 interventional study of Lazertinib and Amivantamab in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 249 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
776
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 20
776 · median 67
Started
2021
with 2 others
Phase 3
3 of 20
none open now
Primary completion
2023-07
later than 0 of 10 live
Registered
8th of 20
by date
Lead sponsor
6 of 20
Janssen Research & Development, LLC

Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lazertinib

lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have at least 1 , according to (RECIST) version 1.1, that has not been previously irradiated
  • Participant must have or cytologically confirmed, locally advanced or , non-squamous non-small cell lung cancer (NSCLC), characterized at or after the time of locally advanced or metastatic disease diagnosis by either epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R mutation
  • A participant with a history of must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization and the participant can be receiving no greater than10 milligrams (mg) prednisone or equivalent daily for the treatment of intracranial disease
  • Participant must have (ECOG) status of 0 or 1
  • Any toxicities from prior systemic anticancer therapy must have resolved to National Cancer Institute (NCI CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade \<= 2 peripheral neuropathy, or Grade \<= 2 hypothyroidism stable on hormone replacement)
  • A participant of must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
  • Participant must have progressed on or after osimertinib monotherapy as the most recent . Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second- line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Participants who received either and/or adjuvant treatment of any type are eligible if progression to locally advanced or metastatic disease occurred at least 12 months after the last dose of such therapy and then the participant progressed on or after osimertinib in the locally advanced or metastatic setting. Treatment with osimertinib must be discontinued at least 8 days (4 half-lives) prior to randomization (that is last dose no later than Day -8)

Exclusion criteria

Exclusion Criteria:

  • Participant received radiotherapy for palliative treatment of NSCLC less than 14 days prior to randomization
  • Participant with symptomatic or progressive
  • Participant has history of or current evidence of , or participant has spinal cord compression not definitively treated with surgery or radiation
  • Participant has known small cell transformation
  • Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
  • Participant has a history of cardiovascular disease including, but not limited to diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to randomization; myocardial infarction; unstable angina; stroke; ; coronary/peripheral artery bypass graft; or acute coronary syndrome. Participant has a significant genetic predisposition to venous thromboembolic events. Participant has a prior history of venous thromboembolic events and is not on appropriate therapeutic anticoagulation as per National Comprehensive Cancer Network or local guidelines
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
776 participants (actual)

Study arms

  • Experimental
    Arm A: LACP/ACP-L

    LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression.

    Drug: Lazertinib · Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin

  • Active comparator
    Arm B: CP (Carboplatin and Pemetrexed)

    Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.

    Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)

    Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.

    Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    Arm A2 (Extension Cohort): ACP-L

    Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression.

    Drug: Lazertinib · Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    Arm C2 (Extension Cohort): ACP

    Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.

    Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin

Interventions

  • Lazertinib will be administered orally.

    Also known as: JNJ-73841937, YH-25448

  • Amivantamab will be administered as an IV infusion.

    Also known as: JNJ-61186372

  • Pemetrexed will be administered as an IV infusion.

  • Carboplatin will be administered as an IV infusion.

06

What researchers measure

Primary outcomes

  1. Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

    PFS is defined as the time from randomization until the date of objective disease progression or death, whichever came first, as assessed by BICR according to RECIST version 1.1. Progressed disease: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).

    Time frame: From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)

  2. Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Follow-up for the extension cohort is still ongoing and thus results from the analysis that includes the extension cohort will be reported up on study completion.

    Time frame: up to 4 years 10 months

  3. Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review

    Time frame: Up to 4 years 10 months

Secondary outcomes

  1. Main Study+ Extension Cohort: Objective Response Rate as Assessed by Blinded Independent Central Review

    Time frame: Up to 4 years 10 months

  2. Main Study+ Extension Cohort: Overall Survival

    Time frame: Up to 4 years 10 months

  3. Main Study+ Extension Cohort: Duration of Response as Assessed by Blinded Independent Central Review

    Time frame: Up to 4 years 10 months

  4. Main Study+ Extension Cohort: Time to Subsequent Therapy

    Time frame: Up to 4 years 10 months

  5. Main Study+ Extension Cohort: Progression-free Survival (PFS) After First Subsequent Therapy (PFS2)

    Time frame: Up to 4 years 10 months

  6. Main Study+ Extension Cohort: Time to Symptomatic Progression

    Time frame: Up to 4 years 10 months

  7. Main Study+ Extension Cohort: Intracranial Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review

    Time frame: Up to 4 years 10 months

  8. Main Study: Number of Participants With Adverse Events (AEs)

    Time frame: Up to 4 years 10 months

  9. Main Study+ Extension Cohort: Number of Participants With Adverse Events (AEs) by Severity

    Time frame: Up to 4 years 10 months

  10. Main Study+ Extension Cohort: Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Up to 4 years 10 months

  11. Main Study+ Extension Cohort: Serum Concentration of Amivantamab

    Time frame: Up to 4 years 10 months

  12. Main Study+ Extension Cohort: Plasma Concentration of Lazertinib

    Time frame: Up to 4 years 10 months

  13. Main Study + Extension Cohort: Number of Participants With Serum Anti-amivantamab Antibodies

    Time frame: Up to 4 years 10 months

  14. Main Study+ Extension Cohort: Change From Baseline With Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NSCLC-SAQ)

    Time frame: Up to 4 years 10 months

  15. Main Study+ Extension Cohort: Change From Baseline With European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

    Time frame: Up to 4 years 10 months

  16. Main Study+ Extension Cohort: Change From Baseline With Patient-Reported Outcomes Measurement Information System -Physical Function (PROMIS-PF)

    Time frame: Up to 4 years 10 months

07

Results

Posted Apr 16, 2025

Participant flow

A total of 657 participants were enrolled in the main study. During the study, a separate open-label randomized extension cohort was added. A total of 119 participants were enrolled into the extension cohort. Main study results are alone reported for primary completion date (PCD; 10-July-2023).

Participant flow — Overall Study
MilestoneMain Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP])
Started263263131119
Treated (safety analysis set)263243130119
Completed6765260
Not completed196198105119
Withdrew: Withdrawal by subject92960
Withdrew: Lost to follow-up1000
Withdrew: Study participation ongoing18616999119

Outcome measures

PrimaryMain Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

PFS is defined as the time from randomization until the date of objective disease progression or death, whichever came first, as assessed by BICR according to RECIST version 1.1. Progressed disease: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).

Time frame:
From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)
Reported as:
Median · months
Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
monthsMain Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)
Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)8.31 (6.77 to 9.10)4.17 (4.04 to 4.44)6.28 (5.55 to 8.41)
Statistical analysis
  • Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.44 · 95% CI 0.35 to 0.56
  • Main Study: Arm B: Carboplatin + Pemetrexed (CP) vs Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.48 · 95% CI 0.36 to 0.64
PrimaryMain Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

Follow-up for the extension cohort is still ongoing and thus results from the analysis that includes the extension cohort will be reported up on study completion.

Time frame:
up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Objective Response Rate as Assessed by Blinded Independent Central Review
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Overall Survival
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Duration of Response as Assessed by Blinded Independent Central Review
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Time to Subsequent Therapy
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Progression-free Survival (PFS) After First Subsequent Therapy (PFS2)
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Time to Symptomatic Progression
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Intracranial Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study: Number of Participants With Adverse Events (AEs)
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Number of Participants With Adverse Events (AEs) by Severity
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Number of Participants With Clinical Laboratory Abnormalities
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Serum Concentration of Amivantamab
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Plasma Concentration of Lazertinib
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study + Extension Cohort: Number of Participants With Serum Anti-amivantamab Antibodies
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Change From Baseline With Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NSCLC-SAQ)
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Change From Baseline With European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

SecondaryMain Study+ Extension Cohort: Change From Baseline With Patient-Reported Outcomes Measurement Information System -Physical Function (PROMIS-PF)
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

PrimaryMain Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review
Time frame:
Up to 4 years 10 months

Results for this outcome have not been posted.

Adverse events

Collected over From Cycle 1 Day 1 up to 1 year 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)69/263 (26.2%)137/263 (52.1%)261/263 (99.2%)
Main Study: Arm B: Carboplatin + Pemetrexed (CP)65/263 (24.7%)49/243 (20.2%)222/243 (91.4%)
Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)27/131 (20.6%)42/130 (32.3%)129/130 (99.2%)
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventMain Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)
ThrombocytopeniaBlood and lymphatic system disorders22/2635/2434/130
NeutropeniaBlood and lymphatic system disorders21/2636/2432/130
Febrile NeutropeniaBlood and lymphatic system disorders20/2635/2432/130
LeukopeniaBlood and lymphatic system disorders10/2631/2430/130
Infusion Related ReactionInjury, poisoning and procedural complications9/2630/2432/130
DyspnoeaRespiratory, thoracic and mediastinal disorders2/2632/2434/130
PneumoniaInfections and infestations8/2635/2430/130
AnaemiaBlood and lymphatic system disorders8/2632/2432/130
NauseaGastrointestinal disorders8/2630/2431/130
PneumonitisRespiratory, thoracic and mediastinal disorders7/2630/2431/130
Most frequent other events
Showing 10 of 64
Most frequent other events
EventMain Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)
NeutropeniaBlood and lymphatic system disorders173/26398/24373/130
ThrombocytopeniaBlood and lymphatic system disorders156/26369/24357/130
Infusion Related ReactionInjury, poisoning and procedural complications142/2631/24374/130
AnaemiaBlood and lymphatic system disorders141/26396/24350/130
ParonychiaInfections and infestations132/2631/24348/130
NauseaGastrointestinal disorders130/26390/24358/130
RashSkin and subcutaneous tissue disorders125/26312/24356/130
StomatitisGastrointestinal disorders120/26321/24341/130
LeukopeniaBlood and lymphatic system disorders106/26367/24337/130
HypoalbuminaemiaMetabolism and nutrition disorders104/26321/24329/130

Baseline characteristics

Only main study (N=657) results are reported, thus column "Total participants" presents main study data. Per protocol, extension cohort analysis was not included in main study primary analysis. Extension cohort results will be reported later, upon analysis completion, at which point arms A2 and C2 details will be reported. For reporting purpose of extension cohort at this time since data is still not available, single combined arm for extension cohort (A2/C2) is presented with '0' participants.

Age, Continuous
Age, Continuous(years)Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP])Total
Mean60.3 ± 10.9660.6 ± 10.1361.2 ± 10.06—60.6 ± 10.44
Sex: Female, Male
Sex: Female, Male(Participants)Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP])Total
Female16815781—406
Male9510650—251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP])Total
Hispanic or Latino22239—54
Not Hispanic or Latino234234118—586
Unknown or Not Reported764—17
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP])Total
American Indian or Alaska Native031—4
Asian12512763—315
Native Hawaiian or Other Pacific Islander000—0
Black or African American413—8
White12912360—312
More than one race020—2
Unknown or Not Reported574—16
Region of Enrollment
Region of Enrollment(Participants)Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L)Main Study: Arm B: Carboplatin + Pemetrexed (CP)Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP)Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP])Total
ARGENTINA560—11
BELGIUM1033—16
BRAZIL10136—29
BULGARIA011—2
CANADA7114—22
CHINA454015—100
CZECH REPUBLIC111—3
FRANCE14187—39
GERMANY340—7
HONG KONG020—2
INDIA1484—26
ISRAEL643—13
ITALY201911—50
JAPAN17249—50
MALAYSIA458—17
MEXICO542—11
NETHERLANDS142—7
POLAND194—14
PORTUGAL421—7
RUSSIAN FEDERATION100—1
SOUTH KOREA252117—63
SPAIN302413—67
SWEDEN310—4
TAIWAN10177—34
TURKEY1054—19
UNITED KINGDOM8102—20
UNITED STATES977—23
08

Study locations

249 sites

Showing the first 100 of 249 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Shih JY, Wang J, Wang Y, Wang J, Lee SH, Azuma K, Takahashi T, Tan JL, Lin CC, Ganguly S, Lee VH, Turna ZH, Sharma R, Kim YJ, Chu PL, Shah S, Diorio B, Cho BC. Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup. Transl Lung Cancer Res. 2026 Sep 30;15(9):284. doi: 10.21037/tlcr-2026-0202. Epub 2026 Sep 24. PubMed 42870814 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jul 2023, 19 months.

Results were first posted in Apr 2025, 1 year 9 months after primary completion. A results delay was requested in Jul 2024.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 19 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Aug 3, 2021
StartActual
Nov 17, 2021
Primary completionActual
Jul 10, 2023
CompletionEst.
Jul 3, 2028
Results delay requested
Jul 5, 2024
Results first posted
Apr 16, 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42870814 ↗
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42870814 ↗
    + 2 other changes: verification date and site details
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04988295
Responsible party
Sponsor
First posted
Aug 3, 2021
Start date
Nov 17, 2021
Primary completion
Jul 10, 2023
Completion
Jul 3, 2028 (estimated)
Results posted
Apr 16, 2025
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lazertinib · Amivantamab

Start the discussion